Daniel Urbisch, Annette Mehling, Katharina Guth, Tzutzuy Ramirez, Naveed Honarvar, Susanne Kolle, Robert Landsiedel, Joanna Jaworska, Petra S. Kern, Frank Gerberick, Andreas Natsch, Roger Emter, Takao Ashikaga, Masaaki Miyazawa, Hitoshi Sakaguchi
Regulatory Toxicology and Pharmacology, Volume 71, Issue 2, March 2015, Pages 337-35
Abstract
Sensitization, the prerequisite event in the development of allergic contact dermatitis, is a key parameter in both hazard and risk assessments. The pathways involved have recently been formally described in the OECD adverse outcome pathway (AOP) for skin sensitization. One single non-animal test method will not be sufficient to fully address this AOP and in many cases the use of a battery of tests will be necessary. A number of methods are now fully developed and validated. In order to facilitate acceptance of these methods by both the regulatory and scientific communities, results of the single test methods (DPRA, KeratinoSens™, LuSens, h-CLAT, (m)MUSST) as well for a the simple ‘2 out of 3’ ITS for 213 substances have been compiled and qualitatively compared to both animal and human data. The dataset was also used to define different mechanistic domains by probable protein-binding mechanisms. In general, the non-animal test methods exhibited good predictivities when compared to local lymph node assay (LLNA) data and even better predictivities when compared to human data. The ‘2 out of 3’ prediction model achieved accuracies of 90% or 79% when compared to human or LLNA data, respectively and thereby even slightly exceeded that of the LLNA.